Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
IGM Biosciences, Inc.
Servier
Progen Pharmaceuticals
Children's Oncology Group
National Cancer Institute (NCI)
Case Comprehensive Cancer Center